Copyright
©The Author(s) 2023.
World J Gastroenterol. Jan 28, 2023; 29(4): 616-655
Published online Jan 28, 2023. doi: 10.3748/wjg.v29.i4.616
Published online Jan 28, 2023. doi: 10.3748/wjg.v29.i4.616
Inducers | Mechanisms | Compounds |
Class 1 | Inhibition of system Xc- | Erastin, sorafenib, sulfasalazin |
Prevention of cystine import | Glutamate | |
Class 2 | Inhibition of GPX4 | RLS3, DPIs (DPI7, DPI10) |
Class 3 | Degradation of GPX4 | FIN56 |
Depletion of CoQ10 | ||
Class 4 | Initiation of lipid peroxidation | FINO2, PUFAs |
Indirect reduction of GPX4 activity | ||
Inhibitors | ||
Class 1 | Suppression of iron accumulation | Deferoxamine |
Class 2 | Inhibition of lipid peroxidation | Ferrostatin-1, liproxstatin-1, vitamin E |
Unclassified | Dynasore, probucol, selenium, nitroxide XJB-5-131 | |
Bicyclol, rosiglitazone |
- Citation: Kouroumalis E, Tsomidis I, Voumvouraki A. Iron as a therapeutic target in chronic liver disease. World J Gastroenterol 2023; 29(4): 616-655
- URL: https://www.wjgnet.com/1007-9327/full/v29/i4/616.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i4.616